Synthesis and in Vitro and in Vivo Antitumor Activity of a Series of Trans Platinum Antitumor Complexes

Journal of Medicinal Chemistry

Volumn 38, Issue 16, 1995, Pages 3016-3024

  Kelland, Lloyd R ^a   Barnard, Christopher F J ^b   Evans, Iona G ^b   Murrer, Barry A ^b   Theobald, Brian R C ^b   Wyer, Sandra B ^b   Goddard, Phyllis M ^a   Jones, Mervyn ^a   Valenti, Melanie ^a   Bryant, Alexander ^a   Rogers, Paul M ^a   Harrap, Kenneth R ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b JOHNSON MATTHEY TECHNOLOGY CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CELL DNA; CISPLATIN; CISPLATIN DERIVATIVE; PLATINUM DERIVATIVE; SATRAPLATIN; TRANS AMMINEDICHLORO(CYCLOHEXYLAMINE)DIHYDROXOPLATINUM; TRANSPLATIN;

ANIMAL CELL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENCY; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; LETHAL DOSE; MOUSE; NONHUMAN; OVARY CARCINOMA; PLASMACYTOMA; TRANS ISOMER; TUMOR XENOGRAFT;

ANIMAL; ANTINEOPLASTIC AGENTS; CISPLATIN; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMAN; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; PLASMACYTOMA; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; SUPPORT, NON-U.S. GOV'T; TUMOR CELLS, CULTURED;

EID: 0029130172     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm00016a004     Document Type: Article

References (32)

1. Harrap, K. R. Preclinical studies identifying carboplatin as a viable cisplatin alternative. Cancer Treat. Rev. 1985, 12 (suppl. A) 21-33.
2. Kelland, L. R.; Abel, G.; McKeage, M. J.; Jones, M.; Goddard, P. M.; Valenti, M.; Murrer, B. A.; Harrap, K. R. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro (cyclohexyl- amine) platinum (IV) (JM216): an orally active platinum drug. Cancer Res. 1993, 53, 2581-2586.
3. Comess, K. M.; Lippard, S. J. Molecular Aspects ofPlatinum- DNA Interactions. In Molecular Aspects of Anticancer Drug- DNA Interactions; Neidle, S., Waring, M., Eds.; The Macmillan Press Ltd.: London, 1993; Vol. 1, pp 134-168.
4. Lemaire, M. A.; Schwartz, A.; Rahmouni, A. R.; Leng, M. Interstrand crosslinks are preferentially formed at the d (GC) sites in the reaction between cis-diamminedichloroplatinum (II) and DNA. Proc. Natl. Acad. Sci. U. SA. 1991, 88, 1982-1985.
5. Kelland, L. R. New platinum antitumor complexes. Crit. Rev. Oncol. /Hematol. 1993, 15, 191-219.
6. Brabec, V.; Leng, M. DNA interstrand cross-links of transdiamminedichloroplatinum (II) are preferentially formed between guanine and complementary cytosine residues. Proc. Natl. Acad. Sci. U. SA. 1993, 90, 5345-5349.
7. Ciccarelli, R. B.; Solomon, M. J.; Varshavsky, A.; Lippard, S. J. In vivo effects of cis- and trans-diamminedichloroplatinum) on SV40 chromosomes: differential repair, DNA-protein crosslinking, and inhibition of replication. Biochemistry 1985, 24, 7533-7540.
8. Eastman, A.; Barry, M. A. Interaction of trans-diamminedichloroplatinum (II) with DNA: formation of monofunctional adducts and their reaction with glutathione. Biochemistry 1987, 26, 3303-3307.
9. Connors, T. A.; Cleare, M. J.; Harrap, K. R. Structure-activity relationships of the antitumor platinum coordination complexes. Cancer Treat. Rep. 1979, 63, 1499-1502.
10. Farrell, N.; Ha, T. T. B.; Souchard, J.-P.; Wimmer, F. L.; Cros, S.; Johnson, N. P. Cytostatic trans-platinum (II) complexes. J. Med. Chem. 1989, 32, 2240-2241.
11. Van Beusichem, M.; Farrell, N. Activation of the trans geometry in platinum antitumor complexes. Synthesis, characterization and biological activity of complexes with planar ligands pyridine, N-methylimidazole, thiazole and quinoline. The crystal and molecular structure of trans-dichloro bis (thiazole) platinum (II). Inorg. Chem. 1992, 31, 634-639.
12. Farrell, N.; Kelland, L. R.; Roberts, J. D.; Van Beusichem, M. Activation of the trans geometry in platinum antitumor complexes. A survey of the cytotoxicity of trans compounds containing planar ligands in murine L1210 and human tumor panels and studies on their mechanism of action. Cancer Res. 1992, 52, 5065-5072.
13. Coluccia, M.; Nassi, A.; Loseto, F.; Boccarelli, A.; Mariggio, M. A.; Giordano, D.; Intini, F. P.; Caputo, P.; and Natile, G. A transplatinum complex showing higher antitumor activity than the cis congeners. J. Med. Chem. 1993, 36, 510-512.
14. Kelland, L. R.; Barnard, C. F. J.; Mellish, K. J.; Jones, M.; Goddard, P. M.; Valenti, M.; Bryant, A.; Murrer, B. A.; Harrap, K. R. A novel trans-platinum coordination complex possessing in vitro and in vivo antitumor activity. Cancer Res. 1994, 54, 5618-5622.
15. Kaufman, G. B.; Cowan, D. O. Cis- and trans-dichlorodiammine- platinum (II). In Inorganic Synthesis; Kleinberg, J., Ed.; McGraw- Hill Book Co. Inc.: New York, 1963; Vol. 7, pp 239-245.
16. Barnard, C. F. J.; Hydes, P. C.; Griffith, W. P.; Mills, O. S. A stable platinum complex perhydrate adduct; structure of cis,-trans-[PtCl2 (OH) 2 (2-NH2Pr) 2]0. 5H20. J. Chem. Res. (S) 1983, 302-303.
17. Basolo, F.; Bailar, J. C.; Tarr, B. R. The stereochemistry of complex inorganic molecules. X. The stereoisomers of dichloro-(ethylenediamine) platinum (IV) chloride. J. Am. Chem. Soc. 1950, 72, 2433-2438.
18. Kuroda, R.; Neidle, S.; Ismail, I. M.; Sadler, P. J. Crystal and molecular structure of three isomers of dichlorodiamminedi-hydroxoplatinum (IV): cis-trans isomerization on recrystallization from water. Inorg. Chem. 1983, 22, 3620-3624.
19. Giandomenico, C. M.; Abrams, M. J.; Murrer, B. A.; Vollano, J. F.; Rheinheimer, M. I.; Wyer, S. B.; Bossard, G. E.; Higgins, J. D. III. Carboxylation of kinetically inert Pt (IV) hydroxy complexes. An entree into orally active Pt (IV) antitumor agents. Inorg. Chem. 1995, in press.
20. Hills, C. A.; Kelland, L. R.; Abel, G.; Siracky, J.; Wilson, A. P.; Harrap, K. R. Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes. Br. J. Cancer 1989, 59, 527-534.
21. Kelland, L. R.; Mistry, P.; Abel, G.; Loh, S. Y.; O’Neill, C. F.; Murrer, B. A.; Harrap, K. R. Mechanism-related circumvention of cis-diammine-dichloro-platinum (II) acquired resistance using two pairs of human ovarian carcinoma cell lines by ammine/ amine platinum (IV) dicarboxylates. Cancer Res. 1992, 52, 3857-3864.
22. Goddard, P. M.; Valenti, M. R.; Harrap, K. R. The role of murine tumour models and their acquired platinum-resistant counterparts in the evaluation of novel platinum antitumour agents: A cautionary note. Ann. Oncol. 1991, 2, 535-540.
23. Harrap, K. R.; Jones, M.; Siracky, J.; Pollard, L.; Kelland, L. R. The establishment, characterization and calibration of human ovarian carcinoma xenografts for the evaluation of novel platinum anticancer drugs. Ann. Oncol. 1990, 1, 65-76.
24. Loh, S. Y.; Mistry, P.; Kelland, L. R.; Abel, G.; Harrap, K. R. Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (TV) ammine/amine complexes. Br. J. Cancer 1992, 66, 1109-1115.
25. O’Neill, C. F.; Orr, R. M.; Kelland, L. R.; Harrap, K. R. Comparison of platinum (Pt) binding to DNA and removal of total Pt adducts and interstrand crosslinks in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin. Cell. Pharmacol. 1995, 2, 1-7.
26. Zhen, W.; Link, C. J.; O’Connor, P. M.; Reed, E.; Parker, R.; Howell, S. B.; Bohr, V. Increased gene-specific repair of cisplatin interstrand crosslinks in cisplatin-resistant human ovarian cancer cell lines. Mol. Cell Biol. 1992, 12, 3689-3698.
27. Carfagna, P. F.; Poma, A.; Wyrick, S. D.; Holbrook, D. J.; Chaney, S. G. Comparisons of tetrachloro (d, l-trans) 1, 2-diaminocyclo- hexane-platinum (IV) biotransformations in the plasma of Fischer 344 rats at therapeutic and toxic doses. Cancer Chemother. Pharmacol. 1991, 27, 335-341.
28. Pendyala, L.; Krishnan, B. S.; Walsh, J. R.; Arakali, A. V.; Cowens, J. W.; Creaven, P. J. Studies on the human metabolism of iproplatin. Cancer Chemother. Pharmacol. 1989, 25, 10-14.
29. Goddard, P.; Valenti, M.; Kelland, L. R. The role of glutathione (GSH) in determining sensitivity to platinum drugs in vivo in platinum-sensitive and -resistant murine leukemia and plasmacytoma and human ovarian carcinoma xenografts. Anticancer Res. 1994, 14, 1065-1070.
30. Jones, M.; Siracky, J.; Kelland, L. R.; Harrap, K. R. Acquisition of platinum drug resistance and platinum cross resistance patterns in a panel of human ovarian carcinoma xenografts. Br. J. Cancer 1993, 67, 24-29.
31. 2], J. Indian Chem. 1970, 8, 193-194.
32. Hollis, L. S.; Amundsen, A. R.; Stern, E. Chemical and biological properties of a new series of ds-diammineplatinum (II) antitumor agents containing three nitrogen donors. J. Med. Chem. 1989, 32, 128-136.